Citicoline vs Cerebrolysin
Both were tested as neuroprotectants after stroke. Citicoline’s large ICTUS trial was neutral; cerebrolysin meta-analyses show mixed efficacy with good safety.
Citicoline
A naturally occurring intermediate in phosphatidylcholine synthesis, studied as a neuroprotective and cognitive compound.
BEST STUDIED FOR
Nootropic & neuro
Read the cited profile →
Cerebrolysin
Cerebrolysin is a preparation of low-molecular-weight neuropeptides and amino acids derived from porcine brain.
BEST STUDIED FOR
Stroke-recovery and neurotrophic research
R1 199View product →
Side by side · to buy
Price, purity and dispatch
| Compare | Citicoline | Cerebrolysin60mg |
|---|---|---|
| Price | — | R1,199 |
| Cost per mg | — | R20.0 / mg |
| Purity (Janoshik) | — | On request |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | Request CoA |
| Literature | — | 4 papers → |
| Research focus | Nootropic & neuro | Stroke-recovery and neurotrophic research |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Citicoline | Cerebrolysin | |
|---|---|---|
| The key difference | Choline-donor small molecule | Neurotrophic peptide mixture |
| Class | Nootropic & neuro | Nootropic & neuro |
| Mechanism | Citicoline supplies choline and cytidine for neuronal membrane phospholipids and influences acetylcholine, dopamine and glutamate systems. | Cerebrolysin is a preparation of low-molecular-weight neuropeptides and amino acids derived from porcine brain. |
| Status | Registered medicine in several countries (stroke, cognitive impairment) and a supplement elsewhere; evidence in stroke is debated. | A porcine brain-derived peptide preparation registered in several countries for stroke and dementia; not approved in the US. |
| Reported safety signals | Reviews describe a favourable safety profile. | Meta-analyses of stroke trials report safety comparable to placebo, with mixed efficacy results. |
| A key study | A comprehensive pharmacological and clinical review of citicoline. (Rev Neurol 2022, PMID 36544369) | A pharmacology review of Cerebrolysin reported neurotrophic mechanisms of brain protection and repair. (Drugs Today (Barc) 2012, PMID 22514792) |
WHEN TO RESEARCH WHICH
Both have human stroke data with modest or mixed results. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Citicoline] Citicoline: pharmacological and clinical review, 2022 update — Rev Neurol 2022. PMID 36544369
- [Citicoline] Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial — J Nutr 2021. PMID 33978188
- [Citicoline] Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis — Nutrients 2023. PMID 36678257
- [Cerebrolysin] The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair — Drugs Today (Barc) 2012. PMID 22514792
- [Cerebrolysin] Cerebrolysin: a review of its use in dementia — Drugs Aging 2009. PMID 19848437
- [Cerebrolysin] Cerebrolysin for vascular dementia — Cochrane Database Syst Rev 2019. PMID 31710397
FREQUENTLY ASKED
What is the difference between Citicoline and Cerebrolysin?
Both were tested as neuroprotectants after stroke. Citicoline’s large ICTUS trial was neutral; cerebrolysin meta-analyses show mixed efficacy with good safety.
What is the regulatory status of Citicoline and Cerebrolysin?
Citicoline: Registered medicine in several countries (stroke, cognitive impairment) and a supplement elsewhere; evidence in stroke is debated. Cerebrolysin: A porcine brain-derived peptide preparation registered in several countries for stroke and dementia; not approved in the US.
What safety signals have been reported?
Citicoline: Reviews describe a favourable safety profile. Cerebrolysin: Meta-analyses of stroke trials report safety comparable to placebo, with mixed efficacy results.
Which studies is this comparison based on?
For Citicoline: “Citicoline: pharmacological and clinical review, 2022 update” (PMID 36544369); “Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial” (PMID 33978188); “Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis” (PMID 36678257). For Cerebrolysin: “The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair” (PMID 22514792); “Cerebrolysin: a review of its use in dementia” (PMID 19848437); “Cerebrolysin for vascular dementia” (PMID 31710397).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use